Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
1130 Results for "
Two dimensional chromatography
" in MedChemExpress (MCE) Product Catalog:
Products (1130)
1130 Results for "Two dimensional chromatography" in MCE Product Catalog:
Cat. No.: HY-171881
CAS No.: 864686-48-6
Research Areas:
BI-5521 is an orally active GSK-3 inhibitor with an IC50 of 1.1 nM against GSK-3β. BI-5521 targets the two GSK-3 isoforms with similar potency and exhibits potent inhibitory activity against DYRK1A. By modulating GSK-3 activity, BI-5521 inhibits tumor proliferation and cancer cell growth, exerts cytotoxic effects, and reduces cancer cell viability. It shows consistent chemosensitivity across all subtypes of rhabdomyosarcoma, produces synergistic growth inhibitory effects when combined with SOS1 inhibitors, reduces oral glucose levels, regulates the myofibroblast differentiation pathway, decreases the nuclear localization of YAP/SMAD2/3, and lowers the positive rate of α-SMA in fibroblasts without affecting the apoptosis of CD4 + T cells. BI-5521 can be used in the research of non-small cell lung cancer, pleomorphic rhabdomyosarcoma, type 2 diabetes, pancreatic ductal adenocarcinoma, Alzheimer's disease, bipolar disorder, and metabolic dysfunction-associated steatotic liver disease .
Cat. No.: HY-D3105
Target:
Research Areas:
DCA is a Fluorescent probe for visualization of phase behavior in ER membranes. DCA is an ER-targeting, polarity-responsive NIR ratiometric probe, with its p-toluenesulfonamide group responsible for ER localization; its sensitivity to polarity relies on its donor-π-acceptor (D-π-A) structure, where aniline acts as the donor and dicyanomethylene acts as the acceptor, driving an intramolecular charge transfer (ICT) process upon excitation. In environments with low polarity, such as the closely packed, low water content ERₒ phase of ER membranes, DCA emits at a shorter wavelength, while in high polarity environments like the loosely packed, higher water content ERd phase, ICT leads to a red-shifted emission, allowing discrimination of the two phases via dual NIR emission colors and ratiometric imaging. Ex/Em = 488/570–620 nm and 488/665–735 nm; additional excitation/emission pairs include Ex/Em = 488/631 nm in low polarity 1,4-dioxane and Ex/Em = 488/677 nm in 1,4-dioxane with 30% water, the higher polarity condition. It shows a large Stokes shift of ~170 nm, and pH, viscosity, and biologically relevant species including Cys, GSH, H₂O₂, and metal ions do not exert marked interference on its fluorescence spectra[1].
Cat. No.: HY-W015777R
CAS No.: 105-13-5
Synonyms: P-Methoxy-benzyl alcoho (Standard); (4-Methoxyphenyl)methanol (Standard)
Cat. No.: HY-W020780
CAS No.: 724722-89-8
Synonyms: mPEG5000-Maleimide
Cat. No.: HY-L075
3,061 compounds
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.
As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.
MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
Cat. No.: HY-P812033
Synonyms: ATP6V1E1; ATPase H+ Transporting V1 Subunit E1; ATP6E2; P31; ATP6E; Vma4; ATPase, H+ Transporting, Lysosomal 31kDa, V1 Subunit E1; V-Type Proton ATPase Subunit E 1; Vacuolar Proton Pump Subunit E 1; V-ATPase 31 KDa Subunit; V-ATPase Subunit E 1; ATP6V1E; ATPase, H+ Transporting, Lysosomal 31kDa, V1 Subunit E Isoform 1; ATPase, H+ Transporting, Lysosomal (Vacuolar Proton Pump) 31kD; H(+)-Transporting Two-Sector ATPase, 31kDa Subunit; H+-Transporting ATP Synthase Chain E, Vacuolar; V-ATPase Subunit E1; V-ATPase, Subunit E; ARCL2C
Cat. No.: HY-P812033A
Synonyms: ATP6V1E1; ATPase H+ Transporting V1 Subunit E1; ATP6E2; P31; ATP6E; Vma4; ATPase, H+ Transporting, Lysosomal 31kDa, V1 Subunit E1; V-Type Proton ATPase Subunit E 1; Vacuolar Proton Pump Subunit E 1; V-ATPase 31 KDa Subunit; V-ATPase Subunit E 1; ATP6V1E; ATPase, H+ Transporting, Lysosomal 31kDa, V1 Subunit E Isoform 1; ATPase, H+ Transporting, Lysosomal (Vacuolar Proton Pump) 31kD; H(+)-Transporting Two-Sector ATPase, 31kDa Subunit; H+-Transporting ATP Synthase Chain E, Vacuolar; V-ATPase Subunit E1; V-ATPase, Subunit E; ARCL2C
Gradient elution with sodium acetate buffer-ACN eluent on two ZIC-HILIC homemade columns separates 2-deoxyuridine in under 9 min .
In Vivo:2'-Deoxyuridine (34.42 ng/mL, gavage, 15 min) passes the blood-brain barrier (BBB) to enter the hippocampus of mice brain . 2'-Deoxyuridine (20 mg/kg, gavage, daily for 4 weeks) improves cognition and memory loss and attenuates the damage to the hippocampus in Aβ25-35-induced mice model .
Cat. No.: HY-L951
505 compounds
Macrocyclic scaffolds are increasingly valued in modern drug discovery for their exceptional activity against undruggable targets (proteases, kinases, PPIs). 2026 marks a key commercial breakthrough for oral macrocyclic peptides: enlicitide, the world’s first oral PCSK9 macrocyclic peptide, has received FDA approval. Macrocyclic candidates targeting KRAS and other classic undruggable targets have also entered clinical development, validating macrocyclization as an effective strategy to overcome druggability barriers.
Two core R&D directions lead current macrocyclic drug design: AI-driven de novo generation and structural optimization of small-molecule macrocycles, and macrocyclic peptides based on sequence design and conformational engineering. Macrocycle druggability hinges on embedded linkers, which determine cyclization efficiency, final conformation and drug-like properties. Bifunctional reaction orthogonality is the core linker selection criterion. Our linker library enables stepwise intramolecular cyclization with suppressed side reactions, accommodates varied ring sizes, and covers three key reaction systems: amide condensation, nucleophilic substitution and CuAAC click chemistry.
Built on classical macrocyclization systems, the library is processed through reaction classification, bifunctional orthogonality evaluation, novelty clustering and redundancy removal, with PROTAC long-chain and ADC cleavable linkers explicitly excluded. Featuring rigid, semi-rigid and flexible scaffolds, it is widely applicable to small-molecule macrocycle synthesis and linear peptide cyclization.
Cat. No.: HY-P86954
Synonyms: 3-1 antibody; 6-alpha-mannosidase antibody; Alpha mannosidase 2 antibody; alpha Mannosidase II antibody; Alpha-mannosidase 2 antibody; AMAN II antibody; Golgi alpha mannosidase II antibody; Golgi alpha-mannosidase II antibody; Golgi integral membrane protein 7 antibody; GOLIM7 antibody; 3-1 antibody; 6-alpha-mannosidase antibody; Alpha mannosidase 2 antibody; alpha Mannosidase II antibody; Alpha-mannosidase 2 antibody; AMAN II antibody; Golgi alpha mannosidase II antibody; Golgi alpha-mannosidase II antibody; Golgi integral membrane protein 7 antibody; GOLIM7 antibody; MA2A1_HUMAN antibody; MAN II antibody; Man2a1 antibody; MANA 2 antibody; MANA2 antibody; MANII antibody; Mann II antibody; Mannosidase alpha class 2A member 1 antibody; Mannosidase Two antibody; Mannosidase, alpha type II antibody; Mannosidase, alpha, II antibody; Mannosyl oligosaccharide 1 3 1 6 alpha mannosidase antibody; Mannosyl oligosaccharide 1,3 1,6 alpha mannosidase antibody; Mannosyl-oligosaccharide 1 antibody;
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
